Cardiac Outcomes Studies For Diabetes Drugs Pose Trial Design Challenges
Although FDA's Endocrinologic and Metabolic Drugs Advisory Committee is calling for large, pre-approval safety trials to detect cardiovascular risk for diabetes drugs, the panel noted that conducting those trials are fraught with confounding variables
You may also be interested in...
Sponsors of new type 2 diabetes therapies should be required to provide clinical data that can exclude an unacceptable cardiovascular risk prior to approval, FDA's Endocrinologic and Metabolic Drugs Advisory Committee concluded at a July 1-2 meeting
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.